Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsekimig in Adult Participants With Moderate-to-severe Asthma
NCT06102005Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2023
- Primary completion
- Feb 2026
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of lunsekimig in asthma, sponsored by Sanofi. Started Oct 2023; status: completed.
02
Drugs
lunsekimig
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06102005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06102005.